Muna Therapeutics is a privately held biopharmaceutical company founded in 2020 and based in Copenhagen, Denmark. Muna discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia and Parkinson’s. These disorders impact memory, movement, language, behavior and personality resulting in disability and death of millions of patients around the globe. We focus our groundbreaking science on identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases. Our name reflects this focus: Muna means ‘to remember’ in Old Norse.
| Website | https://munatherapeutics.com/ |
| Revenue | $6.1 million |
| Employees | 55 (39 on RocketReach) |
| Founded | 2020 |
| Industry | Biotechnology Research |
| Keywords | Neurodegenerative Diseases, Alzheimers Research, Cognitive Decline, Brain Health, Dementia Research, Neurological Disorders, Neurology, Drug Development, Biopharmaceutical, Biotechnology, Pharmaceutical Research, Medicine Development, Drug Discovery, Disease Treatment, Innovative Treatments, Therapeutics Research, New Therapies, Clinical Trials |
| Competitors | Roche, Amgen, Novo Nordisk, Biogen, Neurocrine Biosciences, Sage Therapeutics, Alector, Merck AH, Lilly India, Takeda +44 more (view full list) |
Looking for a particular Muna Therapeutics employee's phone or email?
The Muna Therapeutics annual revenue was $6.1 million in 2026.
Anders Hinsby is the COO of Muna Therapeutics.
39 people are employed at Muna Therapeutics.